Adaptyv Biosystems

Adaptyv Biosystems is a pioneering healthcare company located in Lausanne, VD, Switzerland, with a team of eight employees. Operating within the sub-industry of drug discovery and delivery, Adaptyv Biosystems has developed a revolutionary approach to protein synthesis and screening using a nanofluidic chip, which reduces costs by a factor of 100,000 compared to traditional methods. The company’s ambitious goal is to construct the largest protein design database globally within two years, focusing on developing new therapeutics for diseases that are currently without treatment. As a participant in the Y Combinator S21 batch, Adaptyv Biosystems has garnered support from notable institutions including EPFL and Wingman. Their platform not only facilitates the creation of smart medicines and new molecular machines but also promotes the production of new materials from organic inputs without generating toxic byproducts. Leveraging artificial intelligence, Adaptyv Biosystems explores a vast array of potential protein designs, aiming to impact various sectors such as medicine, manufacturing, computation, and power generation. The company also offers a ‘Foundry Early Access’ program, allowing early access to their protein engineering foundry, with service pricing starting at 99 USD per protein. Customers engaging in monthly packages benefit from discounts and preferred access to foundry capacity, with the flexibility to transfer unused credits for up to 12 months.